Repligen Stock Price, News & Analysis

Repligen (NASDAQ:RGEN) announced three new high-performance chromatography resins on Dec. 16, 2025: AVIPure HiPer AAV9, AVIPure HiPer AAV8 affinity resins and HiPer QA anion exchange resin. Built on Tantti DuloCore base bead technology, the convective HiPer resins target next‑generation modalities such as viral vectors and gene therapy.

The company says the resins are engineered to help gene therapy developers accelerate product development, improve molecule stability, and enhance process economics, and that the launch strengthens Repligen's proteins portfolio ahead of broader chromatography resin rollouts planned for 2026.

Repligen (NASDAQ:RGEN) will participate in the 8th Annual Evercore Healthcare Conference taking place Dec 2–4, 2025 in Coral Gables, Florida.

Jason Garland, Chief Financial Officer, will join an analyst-led discussion on Dec 3, 2025 at 1:20 p.m. ET. A live webcast will be available on Repligen’s Investor Relations website at www.repligen.com, with a limited-time replay following the event.

Repligen (NASDAQ:RGEN) will attend five investor conferences in November 2025 with executive participation and webcasts available. Key events: UBS Global Healthcare (Nov 10–12, Palm Beach Gardens; CFO Jason Garland on Nov 10 at 11:00 a.m. ET), Stifel Healthcare (Nov 11–13, New York; CEO Olivier Loeillot on Nov 11 at 10:00 a.m. ET), Wolfe Research Healthcare (Nov 17–19, New York; CFO Jason Garland on Nov 18 at 12:40 p.m. ET), Jefferies Global Healthcare (Nov 18–20, London; CEO Olivier Loeillot on Nov 18 at 8:30 a.m. ET/1:30 p.m. GMT), and Stephens Annual Investment (Nov 18–20, Nashville; CFO one-on-ones on Nov 19).

A live webcast of presentations will be available on Repligen’s Investor Relations website and replayed for a limited time.

Repligen (NASDAQ:RGEN) reported Q3 2025 revenue of $189M, up 22% reported and 18% organic year‑over‑year, and raised full‑year revenue guidance to $729M–$737M. The company said all franchises and geographies posted double‑digit growth, consumables and capital equipment grew >20%, and Process Analytics equipment placements hit a record quarter after the SoloVPE PLUS launch.

Q3 GAAP net income was $15M and adjusted net income was $26M; GAAP EPS was $0.26 and adjusted EPS was $0.46. Cash and cash equivalents were $749M at Sept 30, 2025. FY2025 adjusted guidance includes organic, non‑COVID growth of 14%–15.5%, adjusted operating income of $98M–$100M, and adjusted EPS of $1.65–$1.68.

Repligen (NASDAQ:RGEN) will report its third quarter 2025 financial results on Tuesday, October 28, 2025. A press release will be issued before the market opens, followed by a conference call at 8:30 a.m. ET to discuss business updates and results for the three- and nine-month periods ended September 30, 2025.

The live call is accessible toll-free at (800) 715-9871 (U.S.) or (646) 307-1963 (international) with no passcode required. A webcast will be available and archived via the company Investor Relations website, and a replay will be posted after the event.

Repligen Corporation (NASDAQ:RGEN), a bioprocessing technology leader in life sciences, has announced its participation in three major healthcare conferences in September 2025:

• Wells Fargo Healthcare Conference (Sept 3-5, Boston) - CEO Olivier Loeillot to join analyst discussion on Sept 4 at 8:00 a.m. ET
• Deutsche Bank Healthcare Summit (Sept 10-11, NYC) - CFO Jason Garland to hold 1x1 meetings on Sept 10
• Bank of America Global Healthcare Conference (Sept 23-25, London) - CEO Olivier Loeillot to participate in analyst discussion on Sept 25 at 6:35 a.m. ET

Live webcasts will be available on Repligen's Investor Relations website with limited-time replay access.

Repligen (NASDAQ:RGEN) has announced a strategic partnership with Novasign to enhance its bioprocessing digitalization capabilities. The collaboration involves integrating Novasign's machine learning and modeling workflow into Repligen's tangential flow filtration (TFF) systems.

As part of the agreement, Repligen will make an investment in Novasign to support its expansion. The partnership aims to leverage digital twins technology and AI-powered solutions to streamline process development, enable real-time predictive control, and reduce development timelines and costs in bioprocessing operations.

The integration will strengthen Repligen's Process Analytical Technology (PAT)-enabled systems and create opportunities for advanced AI modeling within Repligen platforms.

Repligen (NASDAQ:RGEN) reported strong Q2 2025 financial results with revenue reaching $182 million, marking a 15% year-over-year increase and 17% organic non-COVID growth. The company demonstrated robust performance with orders growing over 20% year-over-year, marking the eighth consecutive quarter of orders exceeding non-COVID revenue.

Key financial metrics include GAAP net income of $15 million ($0.26 per share) and adjusted net income of $21 million ($0.37 per share). The company maintains a strong balance sheet with $709 million in cash and equivalents.

Based on strong execution and visibility, Repligen increased its full-year 2025 revenue guidance to $715-$735 million, representing 12.5-15.5% year-over-year non-COVID organic growth. The company launched ProConnex® MixOne and published its 2024 Sustainability report.

Repligen Corporation (NASDAQ:RGEN) has scheduled its second quarter 2025 financial results announcement for Tuesday, July 29, 2025. The company will release its earnings before market open and host a conference call at 8:30 a.m. ET to discuss business updates and financial results for the three- and six-month periods ended June 30, 2025.

Investors can access the conference call via phone at (800) 715-9871 (domestic) or (646) 307-1963 (international). A webcast will also be available through the company's Investor Relations website. Both the call and webcast will be archived for future access, with replay available at (800) 770-2030 (US) or (609) 800-9909 (international) using passcode 7706699.